MPM BioImpact’s Protagonist Therapeutics PTGX Stock Holding History

MPM BioImpact’s Portfolio PTGX Stock Details PTGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-199,471	Closed	-$17.4M	–	44
2025 Q4	$17.4M	Buy	+199,471	New	+$16.3M	1.99%	24

Other funds holding PTGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

MPM BioImpact's PTGX Position: Q1 2026 in Review

MPM BioImpact sold out of Protagonist Therapeutics (PTGX) in Q1 2026, closing a stake of 199,471 shares — an estimated $17.4M sold.

MPM BioImpact first reported a position in PTGX in Q4 2025 and held it in 1 quarter. The position peaked at $17.4M in Q4 2025. 320 funds tracked by Wall St. Rank hold PTGX as of Q1 2026.

MPM BioImpact reported no remaining Protagonist Therapeutics position as of Q1 2026 after selling out during the quarter.
MPM BioImpact sold 199,471 Protagonist Therapeutics shares in Q1 2026, an estimated $17.4M.
MPM BioImpact first reported a position in Protagonist Therapeutics in Q4 2025 and held it in 1 quarter.
MPM BioImpact's Protagonist Therapeutics position peaked at $17.4M in Q4 2025.
320 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q1 2026.

Based on MPM BioImpact's 13F filing for Q1 2026, filed 15 May 2026.